DiaMedica Therapeutics
DMAC
25 hedge funds and large institutions have $3.93M invested in DiaMedica Therapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 4 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
0% more capital invested
Capital invested by funds: $3.92M → $3.93M (+$6.38K)
0.15% more ownership
Funds ownership: 9.55% → 9.7% (+0.15%)
11% less funds holding
Funds holding: 28 → 25 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLG
Cooperman Leon G
|
+$88.7K |
| 2 |
Renaissance Technologies
New York
|
+$49K |
| 3 |
CFP
Catalyst Financial Partners
Boston,
Massachusetts
|
+$16.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.79K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.65K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$40.7K |
| 2 |
Jane Street
New York
|
-$32.9K |
| 3 |
Two Sigma Investments
New York
|
-$19.2K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$3.56K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.73K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Two Sigma Investments
New York
| – | -$19.2K | -12,149 | Closed |
|
|
ASN
27
Advisory Services Network
Atlanta,
Georgia
| – | -$2.37K | -1,500 | Closed |
|
28
Bank of America
Charlotte,
North Carolina
| – | -$64 | -40 | Closed |
|
29
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | +$38 | +24 | New |
|
DMAC Hedge Fund Activity: Q1 2023 in Review
25 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q1 2023, worth a combined $3.93M — up 0.16% from $3.92M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of DMAC and 1 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 9 added.
The largest buyer was Cooperman Leon G, adding an estimated $88.7K. The largest seller was Dimensional Fund Advisors, cutting an estimated $40.7K.
- 25 institutional investors held DiaMedica Therapeutics (DMAC) as of Q1 2023, down from 28 in Q4 2022.
- Funds reported $3.93M of DiaMedica Therapeutics stock for Q1 2023, up 0.16% quarter-over-quarter.
- 1 fund opened new DiaMedica Therapeutics positions in Q1 2023 and 4 closed out, a net change of -3 holders.
- The largest DiaMedica Therapeutics buyer in Q1 2023 was Cooperman Leon G, an estimated $88.7K added.
- The largest DiaMedica Therapeutics seller in Q1 2023 was Dimensional Fund Advisors, an estimated $40.7K sold.
Based on aggregated 13F filings for Q1 2023.